Vertex announces fda clearance of investigational new drug application for vx-407 for the treatment of autosomal dominant polycystic kidney disease (adpkd)

Boston--(business wire)--vertex pharmaceuticals incorporated (nasdaq: vrtx) today announced that the u.s. food and drug administration (fda) has cleared the investigational new drug application (ind) for vx-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (adpkd) in patients with a subset of pkd1 genetic variants. adpkd is the most common inherited kidney disease, with an estimated 250,000 people in.
VRTX Ratings Summary
VRTX Quant Ranking